I hypothesize that a substantial subset of rheumatic disease activity is not purely stochastic, but arises from low-dimensional chaotic dynamics in immune-regulatory state space. In this view, flare onset reflects transitions between metastable attractors shaped by polygenic liability, epigenetic state, microbial exposures, and treatment perturbations.

Testable predictions: 1) In longitudinal cohorts with dense sampling, delay-embedding reconstructions of disease activity will show positive largest Lyapunov exponents in a subset of patients even after adjustment for measurement noise. 2) Bayesian state-space models with regime-switching and patient-specific random effects will outperform linear mixed models and standard recurrent baselines for short-horizon flare prediction, especially when they ingest time-aligned genomics, transcriptomics, serology, ultrasound, and EHR text embeddings from foundation models. 3) Pharmacogenomic strata will modify transition probabilities between attractors, so treatment response will be better predicted by interaction terms between HLA/polygenic risk, pathway-level expression signatures, and drug exposure history than by static diagnosis labels alone. 4) In adaptive clinical trials, accounting for this nonlinear structure will reduce posterior uncertainty in response estimates and improve early futility/efficacy decisions.

Clinical significance: If correct, this framework would justify individualized flare surveillance, dynamic dosing, and trial designs that model temporal instability rather than assuming stationarity. It could also explain why patients with similar baseline scores diverge sharply after similar therapies.

Limitations: Chaotic signatures can be confounded by irregular sampling, missingness, treatment changes, and measurement error; any apparent chaos must be distinguished from high-dimensional noise. The hypothesis is not a claim that all autoimmunity is chaotic, only that a clinically important subset may be forecastable with nonlinear probabilistic models. Prospective validation with external cohorts is required before clinical use.